Zobrazeno 1 - 10
of 305
pro vyhledávání: ''
Autor:
Maximilian von Laffert, Julian M. M. Rogasch, Jens-Carsten Rückert, Liza Michaels, Christian Furth, Sebastian Ochsenreither, Dirk Böhmer, Bettina Temmesfeld-Wollbrück, Nikolaj Frost, Holger Amthauer, Jens Neudecker, Stephanie Bluemel, Tobias Penzkofer
Publikováno v:
Lung Cancer. 157:66-74
Objectives In patients with NSCLC, current ESTS and ESMO guidelines recommend invasive lymph node (LN) staging with EBUS-TBNA even if FDG-PET/CT is negative for mediastinal LNs if at least one of three risk factors is present (cN1, non-peripheral pri
Autor:
Ariana Pereira García, Christian Rolfo, Luis E. Raez, Andrés F. Cardona, Luis Lara-Mejía, Alejandro Aviles Salas, Enrique Caballé Pérez, Oscar Arrieta, Diego Díaz-García, Ixel Escamilla, Rafael Rosell
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Introduction Brain metastases (BM) are frequent among lung cancer patients, affecting prognosis and quality of life. The International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS) and European Respiratory Society
Autor:
Maria Mayoral, Jose de Arimateia Batista Araujo-Filho, Stephanie Lobaugh, Natasha Rekhtman, Jason C. Chang, Junting Zheng, Andrew J. Plodkowski, Michelle S. Ginsberg, Rocio Perez-Johnston, Valerie W. Rusch
Publikováno v:
Lung Cancer
OBJECTIVES: Distinguishing separate primary lung carcinomas (SPLCs) from intrapulmonary metastases (IPMs) in non-small cell lung cancer (NSCLC) patients is a challenging dilemma in clinical practice. Next-generation sequencing (NGS) was recently show
Autor:
Thomas Tsitsias, Tom Routledge, John Pilling, Lukacs Veres, Lawrence Okiror, Juliet King, Karen Harrison-Phipps, Andrea Bille
Publikováno v:
Lung Cancer. 151:84-90
Objective to validate the proposed N descriptor revision on a large cohort of patients and assess the impact of tumour location on the distribution pattern of lymph node metastases for patients with NSCLC. Methods This is a retrospective review of a
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
Publikováno v:
Lung Cancer. 143:40-46
Objectives Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS. Materials and methods Thirty-seven consecutive patients with advanced LCNEC were selected from the Da
Autor:
Weiqiang Zhao, Mahmoud Abdel-Rasoul, Desmond M. D’Souza, David P. Carbone, Robert E. Merritt, Dan Jones, Peter J. Kneuertz, Terrance M. Williams, Konstantin Shilo
Publikováno v:
Lung Cancer. 143:60-66
This study aimed to evaluate the prognostic and potential therapeutic value of expanded molecular testing of resected early-stage lung ACA.We analyzed 324 patients who underwent lobectomy and lymphadenectomy for clinical Stage III lung ACA between 20
Publikováno v:
Lung Cancer. 142:13-19
Objectives This study is aimed to analyze the survival differences among patients with lung basaloid squamous cell carcinoma (BSCC), keratinizing squamous cell carcinoma (KSCC), and nonkeratinizing squamous cell carcinoma (NKSCC), and explore the pro
Autor:
Jacob Sands, Geoffrey R. Oxnard, Pasi A. Jänne, Frank C. Kuo, Adrian G. Sacher, Tom C. Nguyen, Lynette M. Sholl, Michael Cheng, Priyanka Shivdasani, Ryan S. Alden
Publikováno v:
Lung Cancer. 140:35-41
Objectives Potentially targetable genomic alterations have been identified in lung squamous cell carcinoma (LUSC), but none have yet translated into effective therapy. We examined potential benefits of next generation sequencing (NGS) in a cohort of
Autor:
Horiana B. Grosu, David Ost, Graciela Noguras Gonzalez, Andrea Manzanera, Sudeep Shivakumar, Simon Sun
Publikováno v:
Lung Cancer. 140:55-58
Clinical decisions for NSCLC patients are often based on TNM stage, which does not account for different histological subtype. Whether histological subtype affects survival still remains unclear. The main objective of this study was to determine the
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between